Health Care • Biotechnology: Pharmaceutical Preparations
$3.75 ▲ +0.03
(+0.81%)
MKT CAP: $2.1M • VOL: 5.3K
52W L $3 52W H $41
ROARABLE / RQD
D • 49/100
PIOTROSKI
3 / 9
REVB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.1M | -$8.0M | -$8.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$8.9M | -$15.0M | -$120.3K |
| EBITDA (Normalized) | — | -$8.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.3M | -$18.3M | -$7.3M |
| Capital Expenditures (CapEx) | — | $19.2K | — |
| Free Cash Flow (FCF) | -$8.3M | -$18.3M | -$7.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $10.7M | $6.5M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $8.9M | $4.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR REVB.